Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2011 April;59(2) > Minerva Cardioangiologica 2011 April;59(2):187-95

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

  CATHETER ABLATION TECHNIQUES


Minerva Cardioangiologica 2011 April;59(2):187-95

language: English

Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines

Haitsma D. B., De Groot N. M. S., Jordaens L.

Department of Cardiology/electrophysiology, Erasmus Medical Center, Thoraxcentrum, Rotterdam, The Netherlands


PDF  


Antiarrhythmic drug therapy will continue to play an important role in the treatment of atrial fibrillation (AF). Pharmacological therapy is focused on AF symptom relief and on prevention of tachycardiomyopathy. The choice between the various anti-arrhythmic drugs available, either for rate or rhythm control, mainly depends on the underlying cardiac disease, type of AF and possible side-effects. New anti-arrhythmic drugs in the guidelines — vernakalant and dronedarone — are promising, but further research is required to explore their role in treatment of patients with AF. In this review, we will discuss the role of antiarrhythmic drugs in management of patients with AF according to the new AF guidelines of the European Society of Cardiology.

top of page

Publication History

Cite this article as

Corresponding author e-mail

nmsdegroot@yahoo.com